Psychotherapy with Psilocybin for Depression: Systematic Review

The paper addresses the global burden of depression, noting approximately 280 million affected individuals worldwide and significant mortality from suicide among youths. Conventional antidepressant pharmacotherapies show limited efficacy and adherence, with remission rates only modestly higher than spontaneous remission. This motivates investigation into innovative treatments. Psilocybin, a serotonergic tryptamine found in certain mushrooms, has re-emerged as a potential therapeutic adjunct despite Schedule I status in the U.S. Early clinical studies suggest promise for depression, including treatment-resistant cases, prompting this systematic review of psychotherapy combined with psilocybin for depressive symptoms.

A systematic search (PRISMA-guided) was conducted in April 2022 across ProQuest, PsycInfo, PubMed, ScienceDirect, and Scopus. Search strategy used title-restricted keywords combining “psilocybin” AND depress* AND [“therapy” OR “support” OR “treatment”] with Boolean operators, plus manual reference checking. Inclusion criteria: research articles on psychological therapy for depression supplemented with psilocybin, any population, English or Spanish, no date limits, any clinical trial design. Exclusions: theses, reports, book chapters, protocols, descriptive articles, reviews; studies not using psilocybin therapeutically; pharmacology-only treatments; studies focusing solely on spiritual experiences without psychological measures; primarily physiological brain-effect papers. Data extracted: country, objectives, condition, design, participants, treatment, dosing, measures, results, conclusions. Search flow: 88 records identified; 52 after deduplication; 11 selected for full-text screening; 1 added via references (total 12 full-text); 4 excluded after full-text assessment; 8 studies included for analysis.

• Across all eight included studies, psilocybin-assisted therapy produced significant reductions in depressive symptoms, often rapidly (significant improvements observed as early as 1 day and 1 week after dosing) and with durability up to 6, 8, and 12 months in follow-ups.
• Dose-response: Moderate/high doses outperformed low-dose/placebo comparators. In Griffiths et al. (2016), the high-dose-first group showed much greater initial reductions versus low-dose-first; after crossover, low-dose-first group improved comparably. Ross et al. (2016) similarly showed superiority of psilocybin over niacin placebo.
• Comparative efficacy vs SSRI: Carhart-Harris et al. (2021, NEJM) found no significant difference on the primary outcome (QIDS-SR-16) at week 6 between psilocybin and escitalopram (mean change −8.0 (1.0) vs −6.0 (1.0), p = 0.17). Response: 70% psilocybin vs 48% escitalopram; remission: 57% vs 28% (differences not statistically significant on the primary outcome). Secondary measures often favored psilocybin but with unadjusted CIs and potential underpowering.
• Magnitude of effects: Large effect sizes reported at multiple time points favoring psilocybin. Examples: Davis et al. (2021) GRID-HAMD improved from 22.9 (3.6) at baseline to 8.0 (7.1) at 1 week and 8.5 (5.7) at 4 weeks post-second dose (d ≈ 2.3, p < 0.001). QIDS decreased from 16.7 (3.5) to 6.3 (4.4) 1 day after the first dose, maintained to 4 weeks post-second dose (d ≈ 2.3, p < 0.001). In crossover oncology trials, combined effect sizes reached d ≈ 2.98 (GRID-HAMD) and d ≈ 1.63 (BDI) at 6 months.
• Durability: Gukasyan et al. (2022) reported sustained benefits to 12 months with large effect sizes (GRID-HAMD d = 2.0–2.6, p < 0.001) and stable remission rates on QIDS (58–67%) and BDI-II (58–75%).
• Safety/tolerability: Adverse events primarily mild-to-moderate and transient (headache, dizziness, nausea, tachycardia). No cases of addiction or abuse reported. In the NEJM trial, adverse effects were similar between psilocybin and escitalopram groups.
• Treatment model: All studies emphasized preparatory sessions, two supervised dosing sessions (6–8 h), and integration sessions; many used non-directive psychological support with music therapy; one study used psychotherapy during dosing. High-dose sessions were typically 20–30 mg/70 kg or 25 mg fixed dose; placebos included 1 mg/70 kg psilocybin or 250 mg niacin.

Findings indicate psilocybin-assisted psychotherapy can produce rapid and substantial antidepressant effects, contrasting with traditional antidepressants that often require weeks for onset and months for optimal effect. The therapeutic context is crucial: preparatory work to build trust, supportive presence during dosing, and integration sessions likely contribute to outcomes. Setting elements (quiet space, reclined posture, eye mask, music therapy) support inward focus. Spiritual or mystical-type experiences, when present, may mediate or predict longer-term benefits. Safety profiles in controlled settings show mainly transient, mild adverse effects and low abuse potential, comparing favorably with ongoing side-effect burdens of daily antidepressants. While a head-to-head trial with escitalopram did not show superiority on the primary endpoint at 6 weeks, secondary measures and qualitative advantages (rapid onset, fewer sessions) suggest clinical utility; limited power and expectancy/blinding issues may confound results. Overall, the review supports psilocybin-assisted therapy as a promising approach, particularly for treatment-resistant depression, while underscoring methodological needs for rigorous blinding and expectancy control.

Psilocybin-assisted psychotherapy appears to be an effective and well-tolerated intervention for depressive symptoms, with rapid onset and durable effects observed up to 12 months in some studies. Despite legal and cultural barriers, the accumulating experimental evidence highlights its potential as a novel antidepressant modality and adjunct to psychotherapy. Broader applications may extend to PTSD, addictions, and OCD, contingent on carefully developed protocols and therapist training. As evidence grows, psilocybin could meaningfully expand psychiatric treatment options.

The review is limited by the small number of experimental/comparative studies and lack of access to certain potentially relevant articles. The included studies are concentrated in the U.S. and U.K., limiting generalizability, with sex imbalances and possible bias from participants’ prior psychedelic exposure. There is author and procedural homogeneity across studies. Many trials face challenges in blinding and expectancy masking due to noticeable drug effects, potentially biasing outcomes. Additional double-blind, adequately powered, and methodologically rigorous trials with varied psychotherapeutic modalities and dosing strategies are needed.